Abstract:

Objective　To analyze the efficacy of Di'ao Xinxuekang Capsules combined with diltiazem in the treatment of angina pectoris of coronary heart disease. Methods　A total of 96 patients with angina pectoris of coronary heart disease who were admitted to the First People's Hospital of Zhumadian from March 2022 to July 2024 were selected as the study subjects. According to the treatment plan, the patients were divided into the control group (49 cases) and the study group (47 cases). There were 20 males and 29 females in the control group, aged 54-70 (61.97±3.35) years, course of the disease 5-15 (10.24±1.96) months. There were 19 males and 28 females in the study group, aged 53-70 (62.08±3.46) years, course of the disease 5-16 (10.31±1.89) months. The control group was treated with diltiazem, while the study group was treated with Di'ao Xinxuekang capsules in addition to the treatment of the control group. Both groups received continuous treatment for 3 months. Compare the therapeutic effects and adverse reactions of the two groups, as well as the clinical symptoms (frequency and duration of angina pectoris attacks), cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD)], and levels of serum-related cytokines [serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP) levels, and the ratio of neutrophils to lymphocytes (NLR)] before and after treatment. Independent sample t test, paired t test, and χ² test were used for statistical analysis. Results　The total effective rate of the study group was higher than that of the control group [95.75% (45/47) vs. 77.55% (38/49)] (P<0.05). After treatment, the frequency of angina pectoris attacks in the study group was lower than that in the control group [(2.30±0.49) times/week vs. (3.22±0.51) times/week], and the duration was shorter than that in the control group [(3.22±0.71) min/time vs. (4.61±0.85) min/time] (both P<0.05); the LVEF of the study group was higher than that of the control group [(48.02±0.61)% vs. (45.91±0.52)%], and the LVESD was lower than that of the control group [(40.15±2.98) mm vs. (44.05±3.07) mm] (both P<0.05); the levels of serum NT-proBNP, cTnI, hs-CRP and NLR in the study group were all lower than those in the control group [(246.51±29.52) ng/L vs. (378.54±31.74) ng/L, (0.20±0.04) μg/L vs. (0.39±0.05) μg/L, (3.05±0.74) mg/L vs. (4.65±0.92) mg/L, 1.98±0.35 vs. 2.61±0.39] (all P<0.05). The comparison of the total incidence rates of adverse reactions between the two groups showed no statistically significant difference (P>0.05). Conclusion　The combination of Di'ao Xinxuekang Capsules and diltiazem is effective in treating angina pectoris of coronary heart disease. It can inhibit the occurrence of angina pectoris, reduce inflammatory responses, improve cardiac function, and alleviate the degree of myocardial damage. It also has good safety.

Key words: Coronary heart disease,  Angina pectoris,  Di'ao XinxuekangCapsules,  Diltiazem

摘要：

目的　分析地奥心血康胶囊联合地尔硫卓治疗冠心病心绞痛的效果。方法　选取2022年3月至2024年7月驻马店市第一人民医院收治的96例冠心病心绞痛患者作为研究对象。按照治疗方案，将患者分为对照组（49例）和研究组（47例）。对照组男20例，女29例；年龄54～70（61.97±3.35）岁；病程5～15（10.24±1.96）个月。研究组男19例，女28例；年龄53～70（62.08±3.46）岁；病程5～16（10.31±1.89）个月。对照组采用地尔硫卓治疗，研究组在对照组基础上联合地奥心血康胶囊治疗。两组均持续治疗3个月。比较两组治疗效果和不良反应，治疗前后临床症状（心绞痛发作频次、持续时间）、心功能［左心室射血分数（LVEF）、左心室收缩末期内径（LVESD）］、血清相关细胞因子水平［血清N末端B型利钠肽原（NT-proBNP）、心肌肌钙蛋白I（cTnI）、超敏C反应蛋白（hs-CRP）水平以及中性粒细胞和淋巴细胞比值（NLR）］。采用独立样本t检验、配对t检验和χ²检验进行统计学分析。结果　研究组治疗总有效率高于对照组［95.75%（45/47）比77.55%（38/49）］（P<0.05）。治疗后，研究组心绞痛发作频次少于对照组［（2.30±0.49）次/周比（3.22±0.51）次/周］，持续时间短于对照组［（3.22±0.71）min/次比（4.61±0.85）min/次］（均P<0.05）；研究组LVEF高于对照组［（48.02±0.61）%比（45.91±0.52）%］，LVESD小于对照组［（40.15±2.98）mm比（44.05±3.07）mm］（均P<0.05）；研究组血清NT-proBNP、cTnI、hs-CRP水平和NLR均低于对照组［（246.51±29.52）ng/L比（378.54±31.74）ng/L、（0.20±0.04）μg/L比（0.39±0.05）μg/L、（3.05±0.74）mg/L比（4.65±0.92）mg/L、1.98±0.35比2.61±0.39］（均P<0.05）。两组不良反应总发生率比较，差异无统计学意义（P>0.05）。结论　地奥心血康胶囊联合地尔硫卓治疗冠心病心绞痛效果较好，可抑制心绞痛发作、炎症反应，改善心功能，减轻心肌受损程度，安全性较好。

关键词:

冠心病, 心绞痛, 地奥心血康胶囊, 地尔硫卓